DMD 19646

Introduction
Voriconazole (Vfend™), a second generation triazole, is a potent antifungal agent with activity against a broad spectrum of fungal pathogens (Boucher et al., 2004; Patterson, 2002) . Its pharmacokinetic properties after intravenous (IV) and oral administration have been thoroughly investigated in healthy volunteers (Purkins et al., 2002; Purkins et al., 2003a; Purkins et al., 2003b) and in patients at risk of fungal infections (Lazarus et al., 2002) ; the pharmacokinetic / pharmacodynamic profile has been recently reviewed recently (Theuretzbacher et al., 2006) . These studies show that voriconazole is readily absorbed upon oral administration (oral bioavailability > 90%), and that it is eliminated with a terminal elimination half-life of approximately 6 h. Studies with radioisotope-labeled voriconazole have demonstrated that it is cleared via extensive hepatic metabolism in preclinical species and in humans; less than 2% of the administered dose is excreted as the parent drug in humans and a slightly higher percentage of the dose (<10%) appears as voriconazole in the excreta of other preclinical species -mouse, rat, guinea pig, and dog (Roffey et al., 2003) . After either IV or oral administration to humans, nearly 80% of the voriconazole dose is excreted renally, mostly as metabolites (Purkins et al., 2003b) .
Multiple dose studies have revealed non-linear pharmacokinetics with both C max and AUC τ (area under the plasma concentration-time curve during dosage intervals τ ) increasing more than doseproportionately. For example, a 2-fold increase in oral dose (200 mg to 400 mg) caused 2.8-fold and 3.9-fold increase in C max and AUC DMD 19646 5 al., 2003) . In vitro studies with human liver microsomes (HLM) and expressed enzymes have indicated that the N-oxide metabolite is formed predominantly by CYP3A4, CYP2C19, and to a smaller extent by CYP2C9 (Hyland et al., 2003) . These studies suggested that at low µM concentrations of voriconazole, CYP2C19 plays a major role in the formation of the N-oxide, whereas at low mM concentrations, CYP3A4 appears to be the major contributor. Recently, in vitro studies have shown that oxidative metabolism of voriconazole to the hydroxymethyl metabolite ( Figure 1 ) by human and rat liver microsomes is catalyzed exclusively by CYP3A (Murayama et al., 2007) . Significant alteration of voriconazole clearance in CYP2C19 poor metabolizers, resulting in approximately 4-fold greater exposure to voriconazole, provides evidence for a substantial contribution of CYP2C19 to the clearance of voriconazole in vivo (cf. Theuretzbacher et al., 2006) . Because two key CYP enzymes, CYP3A4 and CYP2C19, play a pivotal role in its metabolic clearance, significant drug interactions involving voriconazole are likely when co-administered with inducers or inhibitors of CYP3A4 and CYP2C19 or with drugs that are predominantly cleared by these enzymes (reviewed by Theuretzbacher et al., 2006) .
The NADPH-dependent oxygenation of functional groups containing soft nucleophiles is often catalyzed by another class of oxidative enzymes, flavin-containing monooxygenase (FMO) (Rodriguez et al., 1999; Krueger and Williams, 2005) . In this study, we demonstrate that, in addition to CYP enzymes, certain FMO isoforms can metabolize voriconazole to N-oxide; we further show that these FMO isoforms contribute significantly to the formation of the N-oxide by HLM, a finding that may significantly affect our understanding of the drug interactions involving voriconazole metabolism. DMD 19646 voriconazole were 9.00 and 8.81 ppm, respectively. Purity of the N-oxide was determined by HPLC.
Metabolism of Voriconazole by Human Liver Microsomes:
Incubations of voriconazole (2 µM) with HLM (1.0 mg/mL) were carried out in phosphate buffer (0.1 M, pH 7.4) containing MgCl 2 (3 mM) at 37 o C. The reactions were initiated by addition of NADPH (2 mM); 200 µL aliquots were removed at defined time points and mixed with 600 µL of ice cold methanol (containing internal standard-1 µM diclofenac) to terminate the reactions. After centrifugation at 10,000xg for 10 min, the supernatants were evaporated to dryness under a stream of nitrogen gas; and the dry residues were dissolved in 10% acetonitrile in water.
Quantitative determination of voriconazole was achieved using HPLC with ultraviolet (UV) detection (see the HPLC-UV analysis section). The conditions for initial velocity with respect of time and protein (<20% depletion of initial voriconazole concentration) were determined, and voriconazole metabolism rate and half life (T 1/2 ) were then calculated as described by Obach and 
Discussion
Voriconazole is an antifungal agent that is known to be cleared predominantly via metabolism in all species tested; for example, only 2% of the administrated dose is recovered in excreta as the parent drug in humans. Its elimination is capacity-limited in preclinical species pomol/min/mg). Under the same experimental conditions, the effect of these inhibitors on the CYP activities was measured using the probe substrates (testosterone for CYP3A4, diclofenac for CYP2C9, and S-mephenytoin for CYP2C19) (dotted bar). B-Voriconazole metabolism by HLM was determined upon co-incubation with CYP3A4-, CYP2C9-, or CYP2C19-specific inhibitory antibody (Anti 3A4, Anti 2C9, Anti 2C19, respectively) and with a mixture of the three CYP inhibitory antibody (ALL IAB) (striped bar); the results are presented as percent of "no inhibition" control as explained in the Methods Section, where the "no inhibition" control was the metabolism resulting from co-incubation with rabbit IgG serum (100%). The effect of IAB on corresponding CYP probe substrates was also measured (dotted bar). The data are the mean of This article has not been copyedited and formatted. The final version may differ from this version. by ketoconazole and by heat-inactivation is shown as striped bar and dotted bar, respectively; data for each sample are reported as mean (n=3).
This article has not been copyedited and formatted. The final version may differ from this version. Kinetic constants were determined based on metabolism experiments with voriconazole (1 µM-8000 µM) and recombinant human FMO enzymes (60 pmol/mL) for 30 minutes in the presence of NADPH. The Michaelis-Menten equation was fitted to the rates of N-oxide formation using non-linear regression approach in WinNonLin software v.4.
